免疫联合靶向治疗在晚期肝癌转化治疗中的研究进展

doi:10.3969/j.issn.1009-976X.2022.01.021

摘要/Abstract

摘要： 随着肝细胞癌（HCC）发病机制研究的深入,晚期肝癌已经进入到了多种方式、多种药物联合使用的综合治疗时代,尤其是免疫治疗、免疫联合抗血管靶向治疗以及肝动脉灌注化疗等降期转化治疗取得了显著的疗效,给晚期肝癌患者带来了希望。目前免疫联合靶向药物治疗晚期肝癌已经成为了国内外研究的热点之一,阿特利珠单抗联合贝伐珠单抗（T+A）方案更是作为一线治疗方案正式写入了多个指南之中。本文就免疫联合靶向治疗研究进展、适用人群、疗效监测方面进行讨论。

关键词: 肝细胞肝癌, 转化治疗, 免疫联合靶向治疗

Abstract: With the in-depth research on the pathogenesis of hepatocellular carcinoma （HCC）, advanced liver cancer has entered the era of comprehensive treatment with multiple methods and combinations of multiple drugs. In particular, immunotherapy, immune checkpoint inhibitors combined with antiangiogenic targeted drugs and hepatic arterial infusion chemotherapy（HAIC） and other down-stage conversion therapy have achieved remarkable efficacy, bringing hope to patients with advanced liver cancer. At present, immunization combined with targeted drugs for the treatment of advanced liver cancer has become one of the research hotspots at home and abroad, and the plan of atezolizumab plus bevacizumab（T+A） has been officially written into several guidelines as the first-line therapy for the advanced liver cancer. This article discusses the research progress, applicable population, and efficacy monitoring of immune combined targeted therapy.

Key words: hepatocellular carcinoma, conversion therapy, immune combined targeted therapy

中图分类号:

R735.7

黄沾任, 宁金月, 李汉卿, 陈念平. 免疫联合靶向治疗在晚期肝癌转化治疗中的研究进展[J]. 岭南现代临床外科, 2022, 22(01): 110-114.

HUANG Zhan-ren, NING Jin-yue, LI Han-qin, CHEN Nian-ping. Advances of the conversion therapy of immune checkpoint inhibitors combined antiangiogenic targeted drugs for advanced hepatocellular carcinoma[J]. Lingnan Modern Clinics In Surgery, 2022, 22(01): 110-114.

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Llovet JM, Ricci S, Mazzaferro V, et al.Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390.
[3] Cheng AL, Kang YK, Chen Z, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
[4] 中华预防医学会肝胆胰疾病预防与控制专业委员会, 中国抗癌协会肝癌专业委员会, 北京医学会外科学分会肝脏学组, 等. 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021版)[J]. 中华肝胆外科杂志, 2021, 27(4): 241-251.
[5] Rahma OE, Hodi FS.The Intersection between Tumor Angiogenesis and Immune Suppression[J]. Clin Cancer Res, 2019, 25(18): 5449-5457.
[6] Khan KA, Kerbel RS.Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa[J]. Nat Rev Clin Oncol, 2018, 15(5): 310-324.
[7] Jain RK.Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy[J]. Nat Med, 2001, 7(9): 987-989.
[8] Ringelhan M, Pfister D, O′Connor T, et al. The immunology of hepatocellular carcinoma[J]. Nat Immunol, 2018, 19(3): 222-232.
[9] Ribatti D, Crivellato E.Immune cells and angiogenesis[J]. J Cell Mol Med, 2009, 13(9A): 2822-2833.
[10] Susen RM, Bauer R, Olesch C, et al.Macrophage HIF-2alpha regulates tumor-suppressive Spint1 in the tumor microenvironment[J]. Mol Carcinog, 2019, 58(11): 2127-2138.
[11] Wu JB, Tang YL, Liang XH.Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy[J]. Onco Targets Ther, 2018, 11:6901-6909.
[12] Finn RS, Qin S, Ikeda M, et al.Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
[13] Casak SJ, Donoghue M, Fashoyin-Aje L, et al.FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma[J]. Clin Cancer Res, 2021, 27(7): 1836-1841.
[14] Galle PR, Finn RS, Qin S, et al.Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2021, 22(7): 991-1001.
[15] Finn RS, Ikeda M, Zhu AX, et al.Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970.
[16] Kudo M, Motomura K, Wada Y, et al.Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial[J]. Liver Cancer, 2021, 10(3): 249-259.
[17] Ren Z, Xu J, Bai Y, et al.Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990.
[18] Han C, Ye S, Hu C, et al.Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)[J]. Front Oncol, 2021, 11:684867.
[19] Bruix J, Qin S, Merle P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064): 56-66.
[20] Qin S, Ren Z, Meng Z, et al.Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21(4): 571-580.
[21] Xu J, Shen J, Gu S, et al.Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011.
[22] 袁国盛, 何伟猛, 胡晓云, 等. 卡瑞利珠单克隆抗体联合阿帕替尼二线治疗不可切除肝细胞癌的临床疗效及安全性分析:一项多中心回顾性研究[J]. 中华肝脏病杂志, 2021, 29(4): 326-331.
[23] Kudo M, Kawamura Y, Hasegawa K, et al.Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update[J]. Liver Cancer, 2021, 10(3): 181-223.
[24] Shen X, Zhao B.Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis[J]. BMJ, 2018, 362:k3529.
[25] Chalmers ZR, Connelly CF, Fabrizio D, et al.Analysis of 100, 000 human cancer genomes reveals the landscape of tumor mutational burden[J]. Genome Med, 2017, 9(1): 34.
[26] 陆荫英, 赵海涛, 程家敏, 等. 肝胆肿瘤分子诊断临床应用专家共识[J]. 临床肝胆病杂志, 2020, 36(07): 1482-1488.
[27] Yarchoan M, Hopkins A, Jaffee EM.Tumor Mutational Burden and Response Rate to PD-1 Inhibition[J]. N Engl J Med, 2017, 377(25): 2500-2501.
[28] Zheng Y, Wang T, Tu X, et al.Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma[J]. J Immunother Cancer, 2019, 7(1): 193.
[29] Xu L, Leng C, Chen L, et al.Hypothyroidism is a predictive factor of superior antitumour efficacy of programmed death 1 inhibitors in hepatocellular carcinoma[J]. Int J Cancer, 2022, 150(3): 472-481.
[30] Mei J, Tang YH, Wei W, et al.Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma[J]. Front Oncol, 2021, 11:618206.
[31] He MK, Liang RB, Zhao Y, et al.Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2021, 13:17552544.
[32] Li Z, Chen Q, Zhang W, et al.Efficacy and Safety of the Arsenic Trioxide/Lipiodol Emulsion in the Transcatheter Arterial Chemoembolization Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma[J]. Can J Gastroenterol Hepatol, 2021, 2021:5565793.
[33] Xie Y, Tian H, Xiang B, et al.Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate-advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes[J]. Medicine (Baltimore), 2021, 100(33): e26958.
[34] Yau T, Kang YK, Kim TY, et al.Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial[J]. JAMA Oncol, 2020, 6(11): e204564.